OCEANIC-STROKE Revives Optimism for Factor XI Inhibitors
Davide Capodanno, Professor of Cardiology at University of Catania, editor-in-Chief of EuroIntervention, shared on X:
”Finally, some good news for Factor XI inhibitors, a class of anticoagulants that was starting to look genuinely unfortunate—full of promising hypotheses and remarkably short on outcomes. OCEANIC-STROKE is positive, according to a press release issued today, and notably soon after the announcement that LIBREXIA-ACS had been stopped for futility. Just as the last nail seemed ready to seal the coffin, the lid reopened and out came asundexian—the same agent for which, after OCEANIC-AF, we had essentially already recited the de profundis.
According to the press release, OCEANIC-STROKE met its primary efficacy and safety endpoints: asundexian 50 mg once daily significantly reduced the risk of ischemic stroke compared with placebo, on top of antiplatelet therapy, in patients after a non-cardioembolic ischemic stroke or high-risk TIA. There was no increase in ISTH major bleeding with asundexian.
So the same drug that failed against apixaban in cardioembolic stroke succeeds against placebo in non-cardioembolic stroke (on a background of antiplatelet therapy), highlighting the fundamentally different nature of thrombi in these two conditions.
It is also notable—judging from this sequence of press releases—that factor XI inhibition currently appears more effective in ischemic stroke (asundexian) than in acute coronary syndromes (milvexian), a scenario almost inverted compared with expectations only a few weeks ago. And several shots remain in the chamber (LIBREXIA-STROKE with milvexian; LILAC, ASTER and MAGNOLIA with the monoclonal antibody abelacimab).
OCEANIC-STROKE press release here.
LIBREXIA-ACS press release here.
Find more posts on Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia